Rankings
▼
Calendar
FATE Q3 2017 Earnings — Fate Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
FATE
Fate Therapeutics, Inc.
$143M
Q3 2017 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$1M
+0.0% YoY
Gross Profit
-$8M
-736.1% margin
Operating Income
-$10M
-1007.8% margin
Net Income
-$11M
-1041.3% margin
EPS (Diluted)
$-0.26
QoQ Revenue Growth
+0.0%
Cash Flow
Operating Cash Flow
-$10M
Free Cash Flow
-$10M
Stock-Based Comp.
$871,000
Balance Sheet
Total Assets
$73M
Total Liabilities
$27M
Stockholders' Equity
$46M
Cash & Equivalents
$43M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$1M
$1M
+0.0%
Gross Profit
-$8M
-$6M
-30.7%
Operating Income
-$10M
-$8M
-23.3%
Net Income
-$11M
-$9M
-22.3%
← FY 2017
All Quarters
Q4 2017 →